HighTower Advisors’s Rein Therapeutics RNTX Stock Holding History

HighTower Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13K	Hold	10,000	–	–	﹤0.01%	3777
2025 Q4	$11.6K	Buy	+10,000	New	+$13.8K	﹤0.01%	3633
2023 Q4	–	Sell	-19,204	Closed	-$29K	–	3884
2023 Q3	$29K	Hold	19,204	–	–	﹤0.01%	3292
2023 Q2	$34K	Sell	19,204 -150	-0.8%	-$231	﹤0.01%	3207
2023 Q1	$24K	Buy	+19,354	New	+$41.5K	﹤0.01%	3135
2022 Q2	–	Sell	-600	Closed	-$6K	–	3595
2022 Q1	$6K	Hold	600	–	–	﹤0.01%	3261
2021 Q4	$7K	Buy	+600	New	+$9.28K	﹤0.01%	3186

Other funds holding RNTX

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

HighTower Advisors's RNTX Position: Q1 2026 in Review

HighTower Advisors held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 10,000 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #3777.

HighTower Advisors first reported a position in RNTX in Q4 2021 and has held it in 7 quarters since. The position peaked at $34K in Q2 2023. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

HighTower Advisors held 10,000 shares of Rein Therapeutics worth $13K as of Q1 2026.
HighTower Advisors left its Rein Therapeutics share count unchanged in Q1 2026.
Rein Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3777 holding.
HighTower Advisors first reported a position in Rein Therapeutics in Q4 2021 and has held it in 7 quarters since.
HighTower Advisors's Rein Therapeutics position peaked at $34K in Q2 2023.
46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.